Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472740 | 0.92 | CYP11B2 (0.42) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL3245456 | 0.88 | GPR119 (0.46) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL31111568 | 0.87 | GPR119 (0.46) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL15472739 | 0.85 | NR1H2 (0.40) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL2344292 | 0.84 | HPGD (0.47) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL31586552 | 0.84 | HPGD (0.47) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL2340756 | 0.84 | HPGD (0.47) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL2343234 | 0.83 | GPR119 (0.43) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL15472744 | 0.83 | GPR119 (0.43) | GPR119HPGDUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL2343236 | 0.83 | GPR119 (0.43) | GPR119HPGDUSP2SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2821/4885HPGD 2600/4885USP2 3818/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2821/4885HPGD 2600/4885USP2 3818/4885 |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2821/4885HPGD 2600/4885USP2 3818/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | GPR119 58/4885HPGD 1697/4885USP2 991/4885 |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2821/4885HPGD 2600/4885USP2 3818/4885 |
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BTK, SYK, LCK | GPR119 2821/4885HPGD 2600/4885USP2 3818/4885 |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2821/4885HPGD 2600/4885USP2 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.